Sutro Biopharma (S090) Stock Forecast & Price Target
S090 Analyst Ratings
Strong Buy
8Buy0Hold1Sell
Based on 9 analysts giving stock ratings to Sutro Biopharma in the past 3 months
S090 Stock 12 Month Forecast
Average Price Target
EUR 46.94▲(308.21% Upside)Based on 9 Wall Street analysts offering 12 month price targets for Sutro Biopharma in the last 3 months. The average price target is EUR 46.94 with a high forecast of EUR 53.72 and a low forecast of EUR 42.98. The average price target represents a 308.21% change from the last price of EUR 11.50.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 53.72
AverageEUR 46.94
LowEUR 42.98
Highest Price TargetHighestEUR 53.72Average Price TargetEUR 46.94Lowest Price TargetLowestEUR 42.98
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| David Nierengarten | Wedbush | EUR 53.72 | buy | 367.16%Upside | Reiterated | 10/22/26 | ||
| Lukas Shumway | Barclays | EUR 50.14 | buy | 336.02%Upside | Reiterated | 10/19/26 | ||
| Andres Y. Maldonado | H.C. Wainwright | EUR 44.77 | buy | 289.30%Upside | Reiterated | 10/16/26 | ||
| Yanan Zhu | Wells Fargo | EUR 43.87 | buy | 281.52%Upside | Reiterated | 09/29/26 | ||
| Laura Prendergast | Stifel Nicolaus | EUR 42.98 | buy | 273.73%Upside | Reiterated | 08/17/26 | ||
| Tazeen Ahmad | Bank of America Securities | ― | sell | ― | Reiterated | 08/14/26 | ||
| Supawat Thongthip | Truist Financial | EUR 44.77 | buy | 289.30%Upside | Reiterated | 08/13/26 | ||
| Charles Zhu | LifeSci Capital | EUR 48.35 | buy | 320.45%Upside | Reiterated | 08/12/26 | ||
| Tara Bancroft | TD Cowen | ― | buy | ― | Reiterated | 08/12/26 | ||
| Andrew Berens | Leerink Partners | EUR 34.03→EUR 38.50 | buy | 234.80%Upside | Assigned | 05/15/26 | ||
| Joseph Catanzaro | Mizuho Securities | EUR 44.77 | buy | 289.30%Upside | Initiated | 04/30/26 | ||
| Reni Benjamin | Citizens JMP | EUR 31.34→EUR 36.71 | buy | 219.23%Upside | Reiterated | 04/23/26 | ||
| James Shin | Deutsche Bank | EUR 45.67→EUR 49.25 | buy | 328.23%Upside | Reiterated | 03/25/26 | ||
| Edward Tenthoff | Piper Sandler | EUR 17.91 | buy | 55.72%Upside | Reiterated | 12/04/25 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| David Nierengarten | 10/22/26 | EUR 53.72 | buy | 367.16%Upside | Reiterated | Wedbush | ||
| Lukas Shumway | 10/19/26 | EUR 50.14 | buy | 336.02%Upside | Reiterated | Barclays | ||
| Andres Y. Maldonado | 10/16/26 | EUR 44.77 | buy | 289.30%Upside | Reiterated | H.C. Wainwright | ||
| Yanan Zhu | 09/29/26 | EUR 43.87 | buy | 281.52%Upside | Reiterated | Wells Fargo | ||
| Laura Prendergast | 08/17/26 | EUR 42.98 | buy | 273.73%Upside | Reiterated | Stifel Nicolaus | ||
| Tazeen Ahmad | 08/14/26 | ― | sell | ― | Reiterated | Bank of America Securities | ||
| Supawat Thongthip | 08/13/26 | EUR 44.77 | buy | 289.30%Upside | Reiterated | Truist Financial | ||
| Charles Zhu | 08/12/26 | EUR 48.35 | buy | 320.45%Upside | Reiterated | LifeSci Capital | ||
| Tara Bancroft | 08/12/26 | ― | buy | ― | Reiterated | TD Cowen | ||
| Andrew Berens | 05/15/26 | EUR 34.03→EUR 38.50 | buy | 234.80%Upside | Assigned | Leerink Partners | ||
| Joseph Catanzaro | 04/30/26 | EUR 44.77 | buy | 289.30%Upside | Initiated | Mizuho Securities | ||
| Reni Benjamin | 04/23/26 | EUR 31.34→EUR 36.71 | buy | 219.23%Upside | Reiterated | Citizens JMP | ||
| James Shin | 03/25/26 | EUR 45.67→EUR 49.25 | buy | 328.23%Upside | Reiterated | Deutsche Bank | ||
| Edward Tenthoff | 12/04/25 | EUR 17.91 | buy | 55.72%Upside | Reiterated | Piper Sandler |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Sutro Biopharma
3 Months
Success Rate14/36 ratings generated profit
39%
Average Return
-8.58%
Copying Reni Benjamin's trades and holding each position for 3 Months would result in 38.89% of your transactions generating a profit, with an average return of -8.58% per trade.
1 Year
Success Rate5/17 ratings generated profit
29%
Average Return
-12.57%
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 29.41% of your transactions generating a profit, with an average return of -12.57% per trade.
2 Years
Success Rate4/12 ratings generated profit
33%
Average Return
-10.71%
Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -10.71% per trade.
S090 Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 9 | 14 | 7 |
| Buy | 5 | 2 | 2 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 14 | 12 | 12 | 16 | 7 |
In the current month, S090 has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. S090 average Analyst price target in the past 3 months is 46.94.
S090 Financial Forecast
HighEUR 0.68
ConsensusEUR -1.47
LowEUR -2.56
S090 Earnings Forecast
Next quarter’s earnings estimate for S090 is -EUR 1.47 with a range of -EUR 2.56 to EUR 0.68. The previous quarter’s EPS was -EUR 2.09. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 44.8M
ConsensusEUR 12.6M
LowEUR 2.24M
S090 Sales Forecast
Next quarter’s sales forecast for S090 is EUR 12.63M with a range of EUR 2.24M to EUR 44.77M. The previous quarter’s sales results were EUR 8.81M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
S090 Stock Forecast FAQ
What is DE:S090’s average 12-month price target, according to analysts?
Based on analyst ratings, Sutro Biopharma’s 12-month average price target is €46.94.
What is DE:S090’s upside potential, based on the analysts’ average price target?
Sutro Biopharma has 308.21% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Sutro Biopharma a Buy, Sell or Hold?
Sutro Biopharma has a consensus rating of Strong Buy, which is based on 8 buy ratings, 0 hold ratings and 1 sell ratings.
What is Sutro Biopharma’s share price target?
The average share price target for Sutro Biopharma is €46.94. This is based on 9 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €53.72, and the lowest forecast is €42.98. The average share price target represents a 308.21% increase from the current price of €11.5.
What do analysts say about Sutro Biopharma?
Sutro Biopharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Street analysts.
How can I buy shares of Sutro Biopharma?
To buy shares of DE:S090, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
